VASOPHARM GMBH

Patent Applications and Registrations

Patent applications and USPTO patent grants for VASOPHARM GMBH.The latest application filed is for "solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions".

Company Profile

6.13.12

VASOPHARM GMBH - Wuerzburg DE
VASOPHARM GMBH - Wurzburg DE
VASOPHARM GMBH; - WURZBURG DE
Vasopharm GmbH - DE DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Solid Pharmaceutical Compositions Comprising Biopterin Derivatives And Uses Of Such Compositions App 20220031703 - SCHEURER; Peter ; et al.	2022-02-03
Solid Pharmaceutical Compositions Comprising Biopterin Derivatives And Uses Of Such Compositions App 20210137927 - SCHEURER; Peter ; et al.	2021-05-13
Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions Grant 10,925,877 - Scheurer , et al. February 23, 2	2021-02-23
Solid Pharmaceutical Compositions Comprising Biopterin Derivatives And Uses Of Such Compositions App 20200046710 - SCHEURER; Peter ; et al.	2020-02-13
Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions Grant 10,493,075 - Scheurer , et al. De	2019-12-03
Solid Pharmaceutical Compositions Comprising Biopterin Derivatives And Uses Of Such Compositions App 20180289714 - SCHEURER; Peter ; et al.	2018-10-11
Solid pharmaceutical compositions comprising biopterin derivatives and uses of suchcompositions Grant 10,016,431 - Scheurer , et al. July 10, 2	2018-07-10
Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions Grant 9,895,372 - Scheurer , et al. February 20, 2	2018-02-20
Solid Pharmaceutical Compositions Comprising Biopterin Derivatives And Uses Of Such Compositions App 20170296543 - SCHEURER; Peter ; et al.	2017-10-19
Solid Pharmaceutical Compositions Comprising Biopterin Derivatives And Uses Of Such Compositions App 20170112836 - SCHEURER; Peter ; et al.	2017-04-27
Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species Grant 9,422,289 - Doblhofer , et al. August 23, 2	2016-08-23
Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species Grant 9,382,252 - Doblhofer , et al. July 5, 2	2016-07-05
Use Of Pteridine Derivatives For The Treatment Of Increased Intracranial Pressure, Secondary Ischemia, And Disorders Associated With An Increased Level Of Cytotoxic Reactive Oxygen Species App 20130131071 - DOBLHOFER; Robert ; et al.	2013-05-23
Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation Grant 8,236,809 - Tegtmeier , et al. August 7, 2	2012-08-07
4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level Grant 7,541,360 - Doblhofer , et al. June 2, 2	2009-06-02

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.